Shimla Online

Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Expected to Grow at a Significant CAGR of 43.4% During the Study Period 2019-30

 Breaking News
  • No posts were found

Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Expected to Grow at a Significant CAGR of 43.4% During the Study Period 2019-30

August 01
14:56 2022
Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Expected to Grow at a Significant CAGR of 43.4% During the Study Period 2019-30

DelveInsight’s “Adeno-Associated Virus Vectors in Gene Therapy Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Adeno-Associated Virus Vectors in Gene Therapy, historical and forecasted epidemiology as well as the Adeno-Associated Virus Vectors in Gene Therapy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Adeno-Associated Virus Vectors in Gene Therapy Overview

Adeno-associated virus hails from the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae. They are small viruses (25-nm) with a genome of single-stranded DNA (~4.7 kb) that can either be the plus (sense) or minus (anti-sense) strand. AAV is replication-defective and depends on a helper virus for effective and productive replication in mammalian cells. However, for choosing AAV as a gene delivery vector depends on:

 

Download Sample Report- https://www.delveinsight.com/sample-request/adeno-associated-virus-vectors-in-gene-therapy-market

 

Regions covered in the report

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Key highlights of the Adeno-Associated Virus Vectors in Gene Therapy Market

  • The Adeno-Associated Viral vector is the safest and effective vehicle that is able to maintain long-term gene and protein expression following a single injection of the vector.
  • Currently, two classes of recombinant AAVs (rAAVs) are in use: single-stranded AAV (ssAAV) and self-complementary AAV (scAAV). rAAV gene therapy strategies include Gene replacement, Gene silencing, Gene addition and Gene editing.
  • The first AAV-based gene therapy drug, Glybera, was approved by the European Medicines Agency (EMA) in 2012 but later in 2017, it was withdrawn from the market mainly due to commercial failure.
  • The present AAV-based Gene therapy market owns two FDA-approved AAV-based gene therapies namely, Luxturna, approved in 2017 for a rare inherited retinal dystrophy, and Zolgensma, approved in 2019 for spinal muscular atrophy.

 

Adeno-Associated Virus Vectors in Gene Therapy Epidemiology Segmentation

In the year 2020, the total prevalent cases of selected indications in which AAV Gene Therapies were administered were estimated to be 2,863,103 in the 7MM. DelveInsight’s Adeno-Associated Virus Vector-Based Gene Therapy Market Report provides historical as well as forecasted epidemiological analysis for the study period 2017-30 for the 7MM segmented into:

 

Adeno-associated virus (AAV) Vector-Based Gene Therapy Market

With advances in bioengineering and genetics, the horizon of the medical approaches giving rise to novel treatment options, such as Gene therapy has also widened. Gene therapy has emerged out as a promising treatment approach for a number of inherited disorders, certain types of cancer, and certain viral infections. The delivery of gene therapy involves “vectors” which can be either viral or non-viral vectors. Out of the several viral vectors, Adeno-associated virus (AAV) vectors are currently among the most frequently used, safest and effective viral vectors for gene therapy delivery. AAV vectors are the leading viral vectors for gene delivery to treat a variety of human diseases.

 

Adeno-Associated Virus Vector-Based Gene Therapy Market Landscape

At the moment, the AAV Vector-Based Gene Therapy Market has only two FDA-approved AAV vector-based gene therapies approved. Spark Therapeutics’ Luxturna is approved for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. It is the first FDA-approved gene therapy for a genetic disease, the first and only pharmacologic treatment for an inherited retinal disease and the first AAV vector gene therapy approved in the United States.

 

Adeno-Associated Virus Vector-Based Gene Therapy Market Insights

DelveInsight estimates that the Adeno-Associated Virus Vector-Based Gene Therapy Market, is anticipated to pick up momentum as companies across the globe are thoroughly working toward the development of new AAV-gene therapies to treat a spectrum of diseases. Key pharmaceutical and biotech companies such as Biomarin Pharmaceutical, Roche (Spark Therapeutics), Sangamo, Pfizer among several others are involved in exploring the AAV vector-based gene therapy for a wide range of indications such as Hemophilia A and B, MPS, and others.

 

Request Sample Report- https://www.delveinsight.com/sample-request/adeno-associated-virus-vectors-in-gene-therapy-market

 

Table of Content

1. Key Insights

2. Executive Summary of Adeno-Associated Virus Vectors in Gene Therapy

3. Competitive Intelligence Analysis for Adeno-Associated Virus Vectors in Gene Therapy

4. Adeno-Associated Virus Vectors in Gene Therapy: Market Overview at a Glance

5. Adeno-Associated Virus Vectors in Gene Therapy: Disease Background and Overview

6. Patient Journey

7. Adeno-Associated Virus Vectors in Gene Therapy Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Adeno-Associated Virus Vectors in Gene Therapy Unmet Needs

10. Key Endpoints of Adeno-Associated Virus Vectors in Gene Therapy Treatment

11. Adeno-Associated Virus Vectors in Gene Therapy Marketed Products

12. Adeno-Associated Virus Vectors in Gene Therapy Emerging Therapies

13. Adeno-Associated Virus Vectors in Gene Therapy: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Adeno-Associated Virus Vectors in Gene Therapy

17. KOL Views

18. Adeno-Associated Virus Vectors in Gene Therapy Market Drivers

19. Adeno-Associated Virus Vectors in Gene Therapy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Adeno-Associated Virus Vectors in Gene Therapy Market Report Highlights

  • In the coming years, the Adeno-Associated Virus Vectors in Gene Therapy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Adeno-Associated Virus Vectors in Gene Therapy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
  • Major players are involved in developing therapies for Adeno-Associated Virus Vectors in Gene Therapy. The launch of emerging therapies will significantly impact the Adeno-Associated Virus Vectors in Gene Therapy market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Adeno-Associated Virus Vectors in Gene Therapy
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

 

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Adeno-Associated Virus Vectors in Gene Therapy market
  • To understand the future market competition in the Adeno-Associated Virus Vectors in Gene Therapy market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Adeno-Associated Virus Vectors in Gene Therapy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Adeno-Associated Virus Vectors in Gene Therapy market
  • To understand the future market competition in the Adeno-Associated Virus Vectors in Gene Therapy market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles